This page lists the SEC filings reported by RA Capital Management.
| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13G | 2024-02-22 | RA CAPITAL MANAGEMENT, L.P. | Cytek Biosciences, Inc. | 6,809,404 | 5.2% | EDGAR |
| SC 13D/A | 2024-02-21 | RA CAPITAL MANAGEMENT, L.P. | Icosavax, Inc. | 0 | 0.0% | EDGAR |
| SC 13D/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | Werewolf Therapeutics, Inc. | 6,179,035 | 15.2% | EDGAR |
| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | Aclaris Therapeutics, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | NanoString Technologies Inc | 0 | 0.0% | EDGAR |
| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | HilleVax, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | Cogent Biosciences, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | 4D Molecular Therapeutics, Inc. | 4,163,211 | 9.7% | EDGAR |
| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | ALPINE IMMUNE SCIENCES, INC. | 5,903,234 | 10.0% | EDGAR |
| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | AN2 Therapeutics, Inc. | 5,551,295 | 18.7% | EDGAR |
| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | Ascendis Pharma A/S | 10,107,400 | 17.5% | EDGAR |
| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | Avidity Biosciences, Inc. | 2,454,533 | 3.3% | EDGAR |
| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | CHIMERIX INC | 8,800,000 | 9.9% | EDGAR |
| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | CureVac N.V. | 2,744,270 | 1.2% | EDGAR |
| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | Day One Biopharmaceuticals, Inc. | 7,809,852 | 9.0% | EDGAR |
| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | Fulcrum Therapeutics, Inc. | 11,609,704 | 18.8% | EDGAR |
| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | GERON CORP | 55,145,502 | 10.0% | EDGAR |
| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | GH Research PLC | 5,587,333 | 10.7% | EDGAR |
| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | Gracell Biotechnologies Inc. | 48,600,221 | 10.0% | EDGAR |
| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | ImmunoGen, Inc. | 26,916,027 | 10.0% | EDGAR |
- Form 13F-HR
- The 13F-HR report is filed quarterly to report securities held by the filer that fall under the SEC's 13F rules.
- Form SC 13D/G
- Reported by persons and groups who own 5% or more of any class of a company's outstanding shares. If the ownership changes by 1% or more, an amendment must be filed.
- Form 3, 4, and 5
- Form 3, 4, and 5 reports are filed to report insider transactions by company officers and directors, and any beneficial owners of more than ten percent of a company's shares. Form 3 is the initial report that must be filed when a person becomes an officer, director, or beneficial owner. Form 4 reports are used to report changes in ownership, while the Form 5 report is used for reporting transactions that should have been reported earlier in a Form 4 filing.